American Society of Hematology

Dr. Barry Coller, who served as president of ASH in 1998, is well known for his research in platelet physiology. His studies of the rare platelet disorder Glanzmann thrombasthenia, which is associated with excessive bleeding, and his development of monoclonal antibodies to the GPIIb/IIIa receptor led to the development of the antiplatelet drug abciximab, a derivative of one of those antibodies, in collaboration with scientists at Centocor. Originally approved by the U.S. Food and Drug Administration in 1994, it is now used worldwide to prevent complications of coronary interventions such as angioplasty and stent insertion in patients with cardiovascular disease. For his scientific achievements, Dr. Coller was awarded the Stratton Medal in 2005 and membership in both the Institute of Medicine and the National Academy of Sciences. He currently serves as the David Rockefeller Professor of Medicine, the Vice President for Medical Affairs, and the Head of the Laboratory of Blood and Vascular Biology at Rockefeller University in New York, as well as Physician-in-Chief of the Rockefeller University Hospital. We encourage you to honor Dr. Coller by sharing your thoughts or stories through the Legends in Hematology Guestbook or by making a special gift to ASH.

J. Evan Sadler, MD, PhD, is Professor of Medicine, Hematology Division, and Professor of Biochemistry and Molecular Biophysics at Washington University School of Medicine, St. Louis. He earned his medical degree and PhD in Biochemistry at Duke University, where he also completed an internship and residency in internal medicine. Dr. Sadler was a Hematology Fellow at the University of Washington, Seattle, where he performed postdoctoral research in Earl Davie's laboratory. Dr. Sadler has been an Associate Editor and currently is an Editorial Board member for Blood, the official journal of ASH. He has been a member of ASH for more than 25 years, and has served the Society as Councillor, Treasurer, member of the Scientific Subcommittee on Hemostasis, Co-Chair of the Committee on Investment and Audit, and Chair or Co-Chair of the Scientific Program Committee. Other honors include the William Dameshek Prize awarded by ASH, and the Distinguished Career Award and Investigator Recognition Award of the International Society on Thrombosis and Haemostasis. He is a member of the American Society for Clinical Investigation and the Association of American Physicians, a Fellow of the American Heart Association, and a Fellow of the American Association for the Advancement of Science.

Dr. Armand Keating is Head of the Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute. He is also Professor of Medicine and Director, Division of Hematology at the University of Toronto, as well as the first incumbent of the Gloria and Seymour Chair in Cell Therapy and Transplantation. Until this year, he was also Chief, Medical Services, Princess Margaret Hospital but relinquished this position to become the first director of the Princess Margaret Hospital Cell Therapy Program. He obtained the M.D. degree from the University of Ottawa, received postgraduate training at the University of Toronto, and undertook further studies at the University of Washington and Fred Hutchinson Cancer Research Center in bone marrow transplantation. Upon his return to Toronto, he established the University of Toronto ABMT program. He was a Research Scientist of the National Cancer Institute of Canada for ten years (with research focusing on leukemic and normal hematopoiesis), and has served on numerous U.S. study sections including the National Cancer Institute Program Projects Review Committee (Subcommittee D), which he chaired. He now serves as Chair of the Translational Research Grants Committee of the Leukemia and Lymphoma Society. He was Chair of the Autologous Blood and Marrow Transplant Registry (Milwaukee), was a Councilor of the American Society of Hematology, and is the immediate past President of the American Society for Blood and Marrow Transplantation. He is also the immediate past president of the Canadian Hematology Society. Currently, he serves as Secretary and an Officer of the American Society of Hematology, and Vice-Chair of the Medical and Scientific Affairs Committee of the Leukemia and Lymphoma Society. Dr. Keating is on the editorial boards of numerous scholarly journals, and serves as co-editor of Bone Marrow Transplantation, associate editor of Biology of Blood and Marrow Transplantation, and guest section editor of Cancer. He is a past editor of Leukemia and Lymphoma .

Dr. Goodrich is currently Chief Science Officer and his responsibilities include oversight of research, protocol development, toxicology, and validation programs. Dr. Goodrich has worked in the blood industry for 17 years during which he has managed technical staff and development programs in the fields of blood preservation and pathogen reduction technologies. He has been awarded 34 patents in the U.S. covering technology in these areas and has published over 70 articles and abstracts in the field of blood chemistry and biology. He currently serves as the Principal Investigator for Navigant's grants from the Department of Defense. Dr. Goodrich has also been actively involved in the development of entrepreneurial organizations from a consulting and advisory role. He is frequently called upon as an invited speaker on the topic of pathogen reduction of blood products throughout the U.S., Europe, and Japan and is an active member of several professional organizations including the American Chemical Society, the Southern California Entrepreneurship Association, the American Association of Blood Banks, the American Society of Hematology, the American Society of Photobiology, and the Parental Drug Association. Most recently, Dr. Goodrich was appointed an Adjunct Professor of Chemistry at Ohio State University.

Mr. Brunoehler founded Cryobanks in 1993 as a cryocenter focusing on infertility. In 1995, he shifted the Company's focus towards building a bank of donated unrelated umbilical cord blood for transplantation. He has been instrumental in developing the Company's proprietary collection and processing system to aid in the quality and viability of each unit stored. His skills in public relations have allowed Cryobanks International to partner with physicians and hospitals nationwide to provide a vehicle that allows patients to donate their baby's cord blood easily and without confusion. This increased attention has also opened many doors engaging Cryobanks in furthering research involving the benefits of cord blood stem cells. Mr. Brunoehler is an Active Member of the American Society of Hematology, a Founding Member of the International Cord Blood Society, and a member of The Cord Blood Work Group of the World Marrow Donor Association. Mr. Brunoehler has lectured in numerous hospitals and universities throughout the country on the subject of cord blood donation. Prior to his work at Cryobanks International, Mr. Brunoehler participated in a wide variety of successful ventures. He owned and operated many different businesses as well as serving in executive level positions in marketing, public relations and new product development capacities in both established and start-up companies, including seven years with the Bell system. Honors have included the Florida Public Relations Association's Golden Image Award of Distinction, being a featured speaker at the National Convention of State Delegates, and numerous awards and accolades in both the corporate and civic arenas including March of Dimes Corporate Volunteer of the Year. He is a graduate of the University of Central Florida.

Dr. Edward Donnall Thomas, known as Don to his friends, was born in a small town in central Texas in 1920. His most notable achievement, the Nobel Prize in Medicine, was awarded in 1990 for his development of bone marrow transplantation, which could cure patients with advanced leukemia. Dr. Thomas served as ASH president in 1988 and is currently Professor Emeritus at the University of Washington and Director Emeritus of the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Thomas will be speaking about his life's work and pioneering discoveries at one of the 2008 ASH Annual Meeting Pioneers in Hematology sessions. We encourage you to honor Dr. Thomas by sharing your thoughts or stories through the Legends in Hematology Guestbook or by making a special gift to ASH.

Nancy Berliner, MD, is Chief of Hematology at Brigham and Women's Hospital in Boston, MA, and a Professor of Medicine at Harvard Medical School. Her areas of interest include anemia, leukemia, DNA diagnostics, and transcriptional regulation of myelopoiesis. Dr. Berliner received her medical degree from Yale University School of Medicine and completed medical residency and fellowship in hematology at Brigham and Women's Hospital. She was the first woman to serve as medical Chief Resident at the Brigham. She then spent over 20 years on the faculty of the Yale University School of Medicine, where she became Professor of Medicine and Genetics. She returned to the Brigham in 2007 to assume the leadership of the Hematology Division. Dr. Berliner was elected to the American Society for Clinical Investigation in 1994 and served as Vice President in 1995. She was a Stohlman Scholar of the Leukemia Society. In 2005, she was named one of the "Best Doctors" in the New York Metropolitan area. She is a fellow of the American Association for the Advancement of Science and a member of the Association of American Physicians. Dr. Berliner has served on the ASH Program Committee, which oversees the ASH annual meeting, and is a veteran of the Executive Committee, having served as Secretary from 2001 - 2004. She was a contributor to the first ASH Self-Assessment Program, has served as Education Program Chair, and was Editor of the 2006 ASH Education Program Book. She has also served on several ASH scientific committees and on the editorial board of Blood. Most recently, Dr. Berliner served as Co-chair of ASH's 50th Anniversary Publications Working Group.

Dr. Munshi is an Associate Professor of Medicine at the Harvard Medical School, an Associate Director of the Jerome Lipper Myeloma Center at the Dana Farber Cancer Institute, an Associate Physician at Brigham and Women's Hospital, and an Attending Physician at Boston VA Healthcare System, all in Boston, Massachusetts. Dr. Munshi is also the Chairman of the Expert Panel on Myeloma for the National VA Healthcare System and a member of the Subcommittee on Growth Factors for the American Society of Hematology. He earned his bachelor of medicine/bachelor of surgery and medical degree in Internal Medicine from the Maharaja Sayajirao University of Baroda, India. His research fellowship in oncology was completed at Johns Hopkins Oncology Center in Baltimore, Maryland, and his haematology/oncology clinical fellowship was completed at Indiana University Medical Center in Indianapolis. Dr. Munshi joined the staff at the Myeloma Center at the University of Arkansas in 1992 in both research and clinical roles and was promoted to Professor of Medicine and Director of the Clinical Gene Transduction Laboratory at the Arkansas Cancer Research Center in July 2000. Dr. Munshi's current research activities are centered around developing novel therapeutic modalities including immunotherapy/vaccine approaches and molecular strategies for myeloma and its translational applications to the clinic. Several promising immunobased therapies have been developed from Dr. Munshi's research, including vaccines using fused myeloma cells and dendritic cells that focus the innate immune response against myeloma. Additionally, he is also the principle investigator on studies evaluating the effects of a VEGF-receptor inhibitor (an anti-angiogenic agent in relapsed myeloma) and the efficacy and biological effects of anti CD-40 antibody as a third-line therapy in myeloma. He has over 150 publications and book chapters, primarily in the field of Myeloma. His grant support is substantial and has included grants from National Institutes of Health, American Cancer Society and VA Research grants. He was awarded a Leukemia Society of America Scholar in Translational Research award. Dr. Munshi has been a member of numerous National Institutes of Health committees.

Dr. Langerak received his undergraduate degree from Arizona State University in Tempe, where he graduated summa cum laude, and his medical degree from the University of Arizona College of Medicine. He fulfilled an internship and residency in Internal Medicine and a fellowship in Hematology and Oncology at the University of Arizona College of Medicine and Arizona Cancer Center. Dr. Langerak is board certified in Internal Medicine by the American Board of Internal Medicine and is a member of the American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Tulsa County Medical Society and the Oklahoma State Medical Association.

Dr. Alex Spira received his Ph.D. from New York University School of Arts and Sciences in May, 1996. In May, 1997, he earned his Medical Degree from New York University School of Medicine. Dr. Spira completed his medical internship and residency at the Hospital of the University of Pennsylvania in 2000. June, 2003, Dr. Spira completed a fellowship in Medical Oncology at Johns Hopkins Hospital, Baltimore, MD. Dr. Spira has received multiple awards, fellowships, and honors which include; NIH Medical Scientist Training Program Fellowship, 1990-1997, Merck Corporation Scholar, 1994-1995, Pediatric AIDS Foundation Fellowship, 1993-1995, and a Harvard University Scholarship, 1987-1990. Dr. Spira is board certified in Internal Medicine and Medical Oncology. A published author, he is a member of American Medical Association, American Society of Clinical Oncology, and American Society of Hematology. Dr. Spira joined Fairfax-Northern Virginia Hematology-Oncology, P.C. in August, 2003. Dr. Spira has a special interest in the treatment of sarcomas and is a member of the new INOVA Musculoskeletal Tumor Program. For more information, please Click Here .

Dr. Ali Moussa graduated from the American University of Beirut School of Medicine in 1994, after he received his undergraduate degree in 1990 (B. S. in biology). He completed his internal medicine residency at the Good Samaritan Hospital/John's Hopkins Medical Center in Baltimore, Maryland in 1998 where he served as chief resident. He was awarded outstanding resident while there. In June 2000, Dr. Moussa completed a fellowship in medical oncology at Baylor Medical Center in Houston, Texas. He is board certified in oncology and scored in the 90th percentile on the exam. Dr. Moussa is an investigator for the National Cancer Institute. Dr. Moussa is a member of the American Medical Association, American Society of Clinical Oncology, Tulsa Medical Society, Oklahoma State Medical Association, and American Society of Hematology.

Dr. Madani is a member of the American Society of Clinical Oncology and the American Society of Hematology. He was recipient of the 2003 Merit award from the American Society of Clinical Oncology. He ranked top foreign medical graduate at the 1990 French medicine internship competition. Dr. Madani's research on leukemia has been published in Blood and Oncology, his research on testicular cancer has been published in the Annals of Oncology and the American Journal of Clinical Oncology.

Alida Podrumar, M.D. recently joined the Medical Oncology practice of longtime physician Dr. John Mehanna. Board certified in medical oncology and internal medicine, Dr. Podrumar comes to Cumberland from Johns Hopkins University Hospital in Baltimore, where she recently completed a bone marrow transplant fellowship. Dr. Porumar completed a fellowship in hematology/oncology at Lenox Hill Hospital in New York and did her internal medicine residency at St. John's Episcopal Hospital in Far Rockaway, New York. A native of Romania, Dr. Podrumar received her medical degree from the University of Medicine in Timisoara, Romania, where she also did her residency in internal medicine. She has published several articles in medical journals and is a member of the American Society of Hematology and American Society of Clinical Oncology. Dr. Podrumar will see patients at the office she shares with Dr. Mehanna, which is located at 904 Seton Drive, Suite 202, in Cumberland. For an appointment, call 301-723-5279.

Dr. Cortese Hassett is Vice President and Chief Science Officer at ITxM Diagnostics. Additionally Dr. Cortese Hassett is a Clinical Assistant Professor of Pathology, School of Medicine at the University of Pittsburgh.

Dr. Arthur Frankel is Director of Hematology/Oncology at Scott & White Hospital in Temple, Texas. He is also Executive Director at the Scott & White Cancer Research Institute and Professor of Medicine at Texas A&M Health Science Center, College of Medicine. Dr. Frankel earned his MD from Harvard Medical School and conducted his Medicine Internship at Yale University. Soon after completing his degree, Dr. Frankel began as a Research Scientist with the National Institute of Health and later completed his Medicine Residency and Oncology Fellowship at Stanford University. He is Board Certified in Internal Medicine, Medical Oncology and Hematology. Dr. Frankel is a member of the American Society of Clinical Oncology, American Society of Hematology and American Association of Cancer Research.

Barry Luskey joined Summit Cancer Care in 2000, bringing with him a wealth of experience in both scientific research and clinical care. A graduate of Stanford University in Stanford, Calif., and the University of Texas Southwestern Medical School in Dallas, Dr. Luskey completed fellowships in hematology and oncology at Brigham and Women's Hospital at Harvard Medical School in Boston, Mass. During fellowship, Dr. Luskey pursued basic research in gene therapy at the Howard Hughes Medical Institute at Children's Hospital in Boston. For the next decade, Dr. Luskey was an attending physician at Baylor University Medical Center in Dallas and in private practice with the nation's largest oncology partnership, Texas Oncology. During this time, he continued clinical research endeavors focusing primarily on the care of hematologic malignancies. Board certified in Internal Medicine, Medical Oncology and Hematology, Dr. Luskey is a member of the American Society of Hematology, the American College of Physicians, the American Society of Clinical Oncology, the Georgia Society of Clinical Oncology and the Georgia Medical Society. He is currently on staff at the Anderson Cancer Institute at Savannah's Memorial Health University Medical Center and the Regional Cancer Center at St. Joseph's/Candler Health System and attends the medical oncology and hematology clinics at Memorial where he teaches resident physicians in training.

Dr. Mattar received his medical degree from St. Joseph University School of Medicine, Beirut, Lebanon in 1993. He completed his internal medicine residency at the University of Kansas School of Medicine - Wichita, Kansas. He also completed a fellowship in Oncology/Hematology and Bone Marrow Transplantation at the University of Alabama, Birmingham, Alabama, in 1999. Dr. Mattar is certified by the American Board of Internal Medicine and is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, the Southwest Oncology Group and the American College of Physicians. Dr. Mattar is Board Certified in Oncology, Hematology, and internal medicine. Dr. Mattar continues to be active in clinical cancer research and is a participant in our Wichita CCOP program and other areas of clinical research with interest and expertise in allogeneic bone marrow transplantation. He is a Clinical Assistant Professor of Internal Medicine at the University of Kansas School of Medicine. In 2005 Dr. Mattar became the Director of the Bone Marrow Transplant Program, which is an integrated program of the Cancer Center of Kansas and Via Christi-St. Francis. Dr. Mattar joined the staff of the Cancer Center of Kansas to continue its mission of providing the highest quality patient care using the latest advances in clinical cancer research.

Upon graduating magna cum laude from the University of California, Los Angeles, Ben Ebrahimi, M.D., attended Baylor College of Medicine and completed oncology and hematology fellowships at the University of Texas MD Anderson Cancer Center. While at MD Anderson Cancer Center, Dr. Ebrahimi was selected as a chief fellow, and awarded a National Cancer Institute Fellowship Research Grant. Dr. Ebrahimi is an active member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO). In addition to his general oncology and hematology practice, his special interests include gastrointestinal malignancies such as colon and pancreatic cancer, of which he has published many abstracts and articles. He also specializes in treating hematological malignancies, lung and breast cancer. One of Wilshire Oncology's missions is access to innovative therapies through clinical trials. As the director of clinical research, Dr. Ebrahimi guides the development of new and promising therapies to patients with various cancers.

Dr. Alexander attended the University of Virginia Medical School. He completed a residency in Internal Medicine and fellowship in Hematology and Oncology at the University of Virginia. While at the University, Dr. Alexander also specialized in bleeding and coagulation disorders. Locally, he now serves on the DVT Committee. Dr. Alexander is board certified in Internal Medicine, Hematology and Medical Oncology. He is an associate professor of Medicine at Eastern Virginia Medical School. Dr. Alexander is a member of the American Society of Clinical Oncology and the American Society of Hematology.

Carl Lenarsky, M.D., specializes in pediatric hematology, oncology, and stem cell transplantation. He is certified by the American Board of Pediatrics in pediatric hematology and oncology and the National Board of Medical Examiners. Dr. Lenarsky serves as director of pediatric hematology/oncology and pediatric stem cell transplantation for Texas Oncology, P.A., as well as director of pediatric hematology/oncology for Medical City Children's Hospital in Dallas, Texas. Dr. Lenarsky received his medical degree in 1977 from New York Medical College in Valhalla, N.Y. He held a pediatrics internship and residency from 1977-1979 at Long Island Jewish Hospital in New Hyde Park, N.Y., a pediatric hematology/oncology fellowship from 1979-1980 at Long Island Jewish Hospital, and a pediatric hematology/oncology fellowship from 1980-1982 at UCLA Medical Center in Los Angeles, Calif. In addition, Dr. Lenarsky was an American Cancer Society clinical fellow from 1980-1981 and an American Cancer Society junior faculty clinical fellow from 1983-1985. Dr. Lenarsky received the Brian Parsons Memorial Scholarship Award for Biology at the State University of New York at New Paltz in 1974. He also received the National Institute of Health Research Scientist Training Award from 1980-1982 and the Robert C. Neerhout Teaching Award in 1986 from the University of California, Los Angeles, Calif. In 2007, Dr. Lenarsky was recognized by Texas Monthly as one of Texas' Super Docs. In 2002, 2004, 2005, 2006, and 2007, D Magazine selected Dr. Lenarsky as one of the best pediatric hematologists/oncologists in Dallas, Texas. He received the 1992 Alumni of the Year Award at State University of New York at New Paltz, honorable mention for Dallas Business Journal's 1998 Health Care Provider Hero Award, and he was elected to the State University of New York's Alumni Honor Roll in 1995. Dr. Lenarsky is a member of Western Society for Pediatric Research, American Society of Hematology, American Society of Blood and Marrow Transplantation, and the American Medical Association.

Carlos A. Alemany, M.D., is board-certified in internal medicine, medical oncology and hematology. He received his medical education at Ponce School of Medicine, Ponce, Puerto Rico, and completed his internship and residency in internal medicine at Cleveland Clinic Foundation in Ohio. Dr. Alemany also completed a fellowship in hematology/oncology at Cleveland Clinic Foundation. He is a member of the American College of Physicians, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Association of American Medical Colleges, Pan-American Medical Association, and Puerto Rico Medical Association.

Charles S. White, III, M.D., specializes in medical oncology and hematology. He is board certified in internal medicine, hematology, and medical oncology. Dr. White has served as vice president of Texas Oncology and as president of the medical staff at Medical City Hospital, Dallas, Texas, since 1988, and on the Texas Oncology Board of Directors since 1986. He is also a member of US Oncology's National Policy Board and Executive Committee of Pharmacy and Therapeutics. Dr. White received his Bachelor of Arts in 1965 from Harvard University in Cambridge, MA, and his medical degree from The University of Pittsburgh School of Medicine, Pittsburgh, Pa., in 1969. He completed an internship in 1970 and a residency in 1971 in internal medicine at Dallas Veterans Administration Hospital, Dallas, Texas. Dr. White completed a residency in internal medicine in 1974 and a combined hematology and medical oncology fellowship from 1974-1976 at The George Washington University Medical Center in Washington, D.C. Dr. White has been named among the best doctors by D Magazine for many years. He is a member of the American Society of Clinical Oncology, Dallas County Medical Society, Texas Medical Association, American Society of Hematology, and Texas Society of Medical Oncology.

Christian Adonizio, MD has practiced Hematology and Oncology in Dunmore, PA since 2002. A graduate of Jefferson Medical College, Doctor Adonizio completed his residency in Internal Medicine from Lankenau Hospital in 1999. He subsequently went on to complete a fellowship in Hematology and Oncology from Fox Chase Cancer Center in 2002. The last year of his fellowship was dedicated to supportive oncology and palliative medicine. Doctor Adonizio also serves as the medical director of VNA Hospice of Lackawanna County.

Having graduated from the University of Pittsburgh, Dr. Katcher received his M.D. from the University of Vermont College of Medicine. He completed a Medical Internship and Residency at George Washington University Hospital as well as an Oncology and Hematology Fellowship. He is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Katcher is board Certified in Internal Medicine, Medical Oncology and Hematology. Currently, he is in private practice with Fairfax-Northern Virginia Hematology-Oncology?s Prince William County offices.

Dr. Grosman is board-certified in internal medicine and hematology/oncology. After receiving his medical degree and PhD in molecular and cellular pharmacology from the University of Miami, he lived in Boston for several years, where he worked as a research associate for Dana-Farber Cancer Institute and completed a hematology/oncology fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Grosman is a past recipient of the American Society of Clinical Oncology's Young Investigator Award. He is presently a Diplomate of the National Board of Medical Examiners and American Board of Internal Medicine. He is an active member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He is the immediate past President on the Executive Committee of the Southern Florida Chapter of The Leukemia & Lymphoma Society.

Dr. Johnson is from western Kentucky and graduated from Murray State University and the University of Louisville School of Medicine. He completed a residency in Internal Medicine at Baylor University in Houston, TX and later specialized in Hematology and Oncology at Vanderbilt University. Dr. Johnson joined COHA in 1995. He is board certified in Medical Oncology and Hematology and is member of the American Society of Clinical Oncology and the American Society of Hematology.

Dr. Davey Daniel is from Rentz, Georgia. He graduated from the University of Georgia and the Johns Hopkins School of Medicine. He trained in Internal Medicine, Medical Oncology and Hematology at Duke University Medical Center. Dr. Daniel joined COHA in 2005. He is currently a member of the American Society of Clinical Oncology and the American Society of Hematology.

A native of Wyoming, Dr. Johnson received his medical degree from the University of Colorado School of Medicine. He completed his internship, medical residency, and fellowship in Hematology and Oncology at Wilford Hall, the United States Air Force Medical Center in San Antonio, Texas. He also completed a visiting fellowship at the Bone Marrow Transplant Unit at Fred Hutchinson Cancer Center in Seattle, Washington. Dr. Johnson is certified by the American Board of Internal Medicine and the Subspecialty Boards of Medical Oncology and Hematology. Prior to joining the Cancer Center of Kansas in 1989, Dr. Johnson was a Staff Oncologist/Hematologist at San Antonio's U.S.A.F. Medical Center and Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Dr. Johnson established the Bone Marrow Transplant Program at St. Francis Regional Medical Center. He is the past director of this transplant program, established for both autologous and allogeneic bone marrow transplants. Following an on-site inspection, this transplant program was approved for participation in the Southwest Oncology Group Research Bone Marrow Transplant Program. This was the first non-university hospital to receive approval. Dr. Johnson is also a Clinical Assistant Professor of Internal Medicine at the University of Kansas School of Medicine - Wichita. He is a fellow of the American College of Physicians, a member of the American Society of Clinical Oncology, the American Society of Hematology, the Southwest Oncology Group, and the National Surgical Adjuvant Breast and Bowel Project. He serves as a member of the Southwest Oncology Group Leukemia and Bone Marrow Transplant Committees.

Dr. Lindquist is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology and American Society of Breast Disease. Her research has been published in journals including The New England Journal of Medicine, Experimental Hematology, and the Journal of Laboratory and Clinical Medicine. Dr. Lindquist is currently the research leader for the US Oncology practices in Northern Arizona, which includes Sedona, Flagstaff, and Prescott Valley. In addition, she serves on the US Oncology Breast Cancer Committee.

Dr. Don Eslin, pediatric hematologist/oncologist, is a member of the Pediatric Hematology/Oncology Department at M. D. Anderson - Orlando. He also serves as a clinical associate professor in the Department of Pediatrics at Florida State University. Dr. Eslin is certified by the American Board of Pediatrics in general pediatrics and pediatric hematology/oncology. Dr. Eslin earned his medical degree from Marshall University School of Medicine in Huntington, West Virginia, and completed a residency in pediatrics through Orlando Health's Arnold Palmer Hospital for Children. He fulfilled a fellowship in pediatric hematology/oncology at Children's Hospital of Philadelphia and held a National Research Fellowship Award from the Kennedy Krieger Institute in Baltimore. He is a member of the American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Florida Medical Association and the Orange County Medical Association.

Donald E. Goodin, MD joined the practice in April 2007. Prior to that, he worked for the Rush Riverside Cancer Institute in Kankakee, IL, since 2004. Dr. Goodin will have staff privileges at Georgetown Memorial Hospital and Waccamaw Community Hospital. Dr. Goodin is an active member of the American Medical Association, American Society of Clinical Oncology and the American Society of Hematology. In his spare time, Dr. Goodin and his wife, Sandy, enjoy the company of their dog, Maggie, cooking, fishing, and "attempts" at the game of golf.

Born in England, and raised in England, Nigeria, and Switzerland, Mr. Scott moved to the US in 1985. He is a principal and executive VP of Vox Medica, Inc., a Philadelphia-based health-care communications group. He is a member of the American Society of Hematology (ASH), and an associate member of the American Society for Clinical Oncology (ASCO). He graduated from the University of Sussex, where he earned an honors degree in biochemistry.

Dr. Berko earned his medical degree from the School of Medical Sciences, Kwame Nkrumah University of Science and Technology in Kumasi, Ghana, and a Master of Public Health from the University of Limburg in Maastricht, Holland. He earned board certification from the American Board of Internal Medicine. Dr. Berko completed a three-year residency at Cook County Hospital in Chicago and a three-year fellowship in oncology/hematology at Cook County Hospital/Rush Cancer Institute in Chicago. Dr. Berko is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Medical Association, the American College of Physicians and the American Society of Internal Medicine. He has been published in several medical journals.

During his residency in internal medicine, Dr. Hesita served as Chief Resident at the University of Oklahoma College of Medicine. He received the award of "Outstanding Fellow of the Year 2005-2006" at Ochsner Clinic Foundation. Dr. Hesita is a member of the American Society of Clinical Oncology, American Society of Hematology, Louisiana State Medical Society, American College of Physicians and the American Medical Association. In addition to his medical degree, Dr. Hesita has a degree in Medical Technology and is certified as a Cytotechnologist through the American Society of Clinical Pathology. He served in the U.S. Army for five and a half years at Fort Carson, Colorado, and at Brooke Army Medical Center in San Antonio.

Dr. Edwin McCreary graduated from St. George's University School of Medicine in 1998, after he received his B.S. in biology from Abilene Christian University in 1990. Dr. McCreary completed his internal medicine residency and internship at the The University of Oklahoma in Tulsa, OK. In July 2006, he completed a fellowship in medical oncology and hematology at New York University in New York, NY. He served as chief fellow while there. He is board eligible in hematology/oncology and board certified in internal medicine. Dr. McCreary is a member of the American Society of Clinical Oncology, American Society of Hematology, and Tulsa Medical Society. He has been an active volunteer in the community; volunteering for such organizations as Big Brothers and Big Sisters and Neighbor for Neighbor Community Clinic.

Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities of several of the company’s therapeutic programs. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and Atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for over a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric techniques to predict leukemic recurrence. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research and is certified by the American Board of Pediatrics.

Ethan J. Wasserman, MD, is a hematologist and oncologist on the staff at the Cancer Institute of New Jersey Hamilton. His specialty is internal medicine. He is also an assistant professor of medicine at UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ. Dr. Wasserman earned his medical degree from Jefferson Medical College in Philadelphia, PA. He holds a master's degree in biology from Saint John's University in New York and a bachelor's degree in speech communications from Yeshiva University in New York. He completed a fellowship in hematology and oncology from UMDNJ-Robert Wood Johnson Medical School where he also completed both his internship and residency. Dr. Wasserman is a diplomate of the American Board of Internal Medicine. He is a member of the American Society of Clinical Oncologists; the American Society of Hematology; the American College of Physicians; and the American Medical Association.

Fabio Volterra, M.D. is a consulting physician at the Eastchester Center for Cancer Care. Dr. Volterra serves as an assistant clinical professor of medicine at Albert Einstein College of Medicine. He is a member of the American College of Physicians, Italian Medical Society, American Medical Society, American Society of Internal Medicine, American Society of Breast Disease and American Society of Hematology.

Swan is a board certified oncologist with Cancer Outreach Associates, PC, in Abingdon, Va. Karen Clawson, a nurse, says she has never met anyone else that measures up to Swan's compassion and dedication to patients. "He truly gives of himself to ease the suffering of others. He always goes the extra mile to meet the needs of all his patients, not only as a physician but also as a caring friend," she says. Along with establishing Cancer Outreach Associates, Swan started the Cancer Outreach Foundation, a nonprofit organization dedicated to helping area cancer patients who may be unable to afford treatment or medication. Reportedly, patients have been known to travel hundreds even thousands of miles to see Swan, not only because of his knowledge and expertise in the hematology/oncology field but also because of his reputation as compassionate and the personable relationships he shares with all his patients. Swan graduated from the University of Illinois College of Medicine in Chicago. He completed an internship at Edward Hines Jr. Hospital in Hines, Ill., and a residency at the University of Texas MD Anderson Cancer Center in Houston, where he became assistant professor of clinical medicine. He is a member of the American Society of Clinical Oncology, American Society of Hematology and American Medical Association. He resides in Abingdon with his wife Sherrie and their three children. He enjoys boating, fishing, reading and the outdoors, particularly the Virginia Creeper Trail.

Dr. Tian, a native of China, joined the medical staff of the Family Cancer Center in July 2003. He is Associate member of the American College of Physicians, the American Society of Hematology and the American Society of Clinical Oncologists. Like his colleagues at FCC he brings to the group a strong background in research. In his spare time, Dr. Tian is an avid soccer player and has been team captain on several teams.

Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer from January 2008. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. Since her arrival she has played a major role in the expansion of the number of later stage clinical trials and the growth and integration of the Clinical Development group within the entire R&D organization. Prior to joining Exelixis, Dr. Schwab served as senior vice president and chief medical officer at Abgenix, Inc., a human antibody- based drug development company that was acquired by Amgen, Inc. in April 2006. Prior to working at Abgenix, Dr. Schwab held various roles of increasing responsibility at Amgen Inc., most recently as therapeutic area leader for the clinical development of Amgen's hematology and oncology pipeline. Dr. Schwab received her Doctor of Medicine degree from the University of Heidelberg, trained at the National Cancer Institute and is board certified in internal medicine and hematology and oncology.

Gregory M. Evans, was appointed to the Board of Directors, and became the Company's President and Chief Executive Officer, in May 2001. He was the Chief Operating Officer from 1998 to 2001 and the Chief Financial Officer from 1983 to 1998. Mr. Evans graduated from the University of California at Berkeley and holds an M.B.A. degree from the Harvard Graduate School of Business.

Dr. Chen became a hematologist in China and passed the United States Medical Licensing Examination (USMLE) in 2002. He currently serves as a reviewer for the Philip Morris External Research Program and is a member of the American Society of Hematology. Dr Chen received his doctoral degree from Shanghai Jiao Tong University, School of Medicine, Biochemistry Institute, Chinese Academy of Science, and University of Southern California. He completed his postdoctoral training at the University of British Columbia and served as an Assistant Professor at the University of Southern California from 1994 to 2001. Dr. Chen received a NIH training grant (1994-1996) for genetic development biology. In his research, he has discovered that myeloma tumors produce a protein, pleiotrophin, that assists tumor growth by a completely novel mechanism in which a type of white cell called a monocyte turns into a new blood vessel. This discovery has opened exciting new avenues in the development of treatment for myeloma patients and the paper has been published in the prestigious Blood (Chen H. et al. 1; 110: 287-95, 2007). Dr. Chen has also developed innovative siRNA technology that has led to new advances in controlling the growth of myeloma tumors in the bone as well as stemming the loss of bone density. The paper, "Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis" has been published in Oncogene (Chen H. et al. 25; 6520-7, 2006) He continues to design new uses for this technology to target anti-myeloma therapies to specific genes.

Dr. Broxmeyer is the Chairman of the Department of Microbiology and Immunology, Scientific Director of the Walther Oncology Center and a Distinguished Professor of the Indiana University School of Medicine. Dr. Broxmeyer is a highly sought after international speaker who is recognized as a founder of the field of cord blood stem cell transplantation. In his 30 year career he has authored over 500 publications and has served as an editor on many peer reviewed journals, including the Senior Editor of the Journal of Hematotherapy and Stem Cell Research.

Harry Staszewski, MD, is Chief of the Division of Oncology/Hematology. Caring for cancer patients since 1986, he also serves as Vice Chair of Winthrop's Institutional Review Board, which oversees clinical trial research conducted at Winthrop, and serves as Principal Investigator in numerous clinical trials exploring innovative therapies for the treatment of cancer. Additionally, he chairs the Hospital's Cancer Committee. A Fellow of the American College of Physicians, Dr. Staszewski is Board Certified in Internal Medicine, Hematology and Oncology. His post-graduate training includes fellowships in Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and in Hematology at Long Island Jewish Hospital. He completed a residency in medicine at North Shore University Hospital and received his medical degree from Yale University School of Medicine. Dr. Staszewski is an Associate Professor of Medicine at the SUNY Stony Brook School of Medicine at Stony Brook. He has published numerous articles in professional journals and presented many lectures on topics related to oncology/hematology. He is a member of the American Society of Clinical Oncology, American Society of Hematology and American Association for Cancer Research.